Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Pediatric Drugs
Erschienen in: Pediatric Drugs 3/2011

01.06.2011 | Review Article

Juvenile Idiopathic Arthritis

New Insights into Classification, Measures of Outcome, and Pharmacotherapy

verfasst von: Dr Michael W. Beresford

Erschienen in: Pediatric Drugs | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Significant advances have taken place in recent years in our understanding of the aetiopathogenesis, anagement, and clinical outcome of juvenile idiopathic arthritis (JIA). Fundamental to this advancement has been international collaborative efforts of the clinical scientific community and all those involved in the multidisciplinary care of children and young people with JIA.
A key factor has been facing the challenge of developing a robust classification system for JIA, a clinically very heterogeneous group of conditions. JIA illustrates the necessity of disease classification to enable scientific progress but also the iterative and evolving process this entails. What is emerging is the imperative to improve our understanding of the biologic and genetic basis of JIA to underpin classification systems.
Growing emphasis is centered on improved holistic care and outcome of children and young people with JIA. The expectation of patients, their families, and clinicians is the goal of inactive disease, remission off treatment, and the health and psychosocial well-being of young people emerging into adulthood. Validated tools that reflect these challenges are being developed, including those measuring disease improvement, flare, remission and minimal disease activity, health-related quality of life, and composite scores of activity and damage.
Clinical research networks have driven success in developing an evidence-base for the treatment of JIA. Randomized comparative trials have demonstrated the benefit of early use of intra-articular corticosteroid injections, and the importance of methotrexate as the first-line, disease-modifying antirheumatic drug in JIA. The introduction of biologic therapies has opened a major new epoch in the medical management of JIA, with recent trials published on etanercept, infliximab, adalimumab, abatacept, tocilizumab, and anakinra.
This review focuses on recent advances in JIA, especially developments in its classification, validation of appropriate measures of holistic outcome, and the specific contribution of established and newer pharmacologic agents available for treating children and young people.
Literatur
1.
Brough R, Cleary G. When does a knee “need” a “joint” assessment? Arch Dis Child Educ Pract Ed 2007; 92(2): ep44–9PubMedCrossRef
2.
Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31(2): 390–2PubMed
3.
Symmons DP, Jones M, Osborne J, et al. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 1996; 23(11): 1975–80PubMed
4.
Beresford MW, Baildam EM. New advances in the management of juvenile idiopathic arthritis: I. Non-biological therapy. Arch Dis Child Educ Pract Ed 2009; 94(5): 144–50PubMedCrossRef
5.
Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25(10): 1991–4PubMed
6.
Foeldvari I, Bidde M. Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol 2000; 27(4): 1069–72PubMed
7.
Fantini F. Classification of chronic arthritides of childhood (juvenile idiopathic arthritis): criticisms and suggestions to improve the efficacy of the Santiago-Durban criteria. J Rheumatol 2001; 28(2): 456–9PubMed
8.
Hofer MF, Mouy R, Prieur AM. Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria. J Rheumatol 2001; 28(5): 1083–90PubMed
9.
10.
11.
Dannecker GE, Quartier P. Juvenile idiopathic arthritis: classification, clinical presentation and current treatments. Horm Res 2009; 72Suppl. 1: 4–12PubMedCrossRef
12.
13.
Prahalad S, Glass DN. A comprehensive review of the genetics of juvenile idiopathic arthritis [abstract]. Pediatr Rheumatol Online J 2008; 6: 11PubMedCrossRef
14.
Berkun Y, Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 2010; 9(5): A319–24PubMedCrossRef
15.
Ellis JA, Munro JE, Ponsonby AL. Possible environmental determinants of juvenile idiopathic arthritis. Rheumatology (Oxford) 2010; 49(3): 411–25CrossRef
16.
Petty RE. Growing pains: the ILAR classification of juvenile idiopathic arthritis. J Rheumatol 2001; 28(5): 927–8PubMed
17.
Merino R, de Inocencio J, Garcia-Consuegra J. Evaluation of revised International League of Associations for Rheumatology classification criteria for juvenile idiopathic arthritis in Spanish children (Edmonton 2001). J Rheumatol 2005; 32(3): 559–61PubMed
18.
Stabile A, Avallone L, Compagnone A, et al. Focus on juvenile idiopathic arthritis according to the 2001 Edmonton revised classification from the International League of Associations for Rheumatology: an Italian experience. Eur Rev Med Pharmacol Sci 2006; 10(5): 229–34PubMed
19.
Minden K, Niewerth M. Juvenile idiopathic arthritis: clinical subgroups and classification. Z Rheumatol 2008; 67(2): 100, 102–6, 108–10PubMedCrossRef
20.
Behrens EM, Beukelman T, Cron RQ. Juvenile idiopathic arthritis classification criteria: loopholes and diagnosis software. J Rheumatol 2007; 34(1): 234; author reply 234-5PubMed
21.
Berntson L, Damgard M, Andersson-Gare B, et al. HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J Rheumatol 2008; 35(10): 2055–61PubMed
22.
Griffin TA, Barnes MG, Ilowite NT, et al. Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets. Arthritis Rheum 2009; 60(7): 2113–23PubMedCrossRef
23.
Muller L, Kellenberger CJ, Cannizzaro E, et al. Early diagnosis of temporomandibular joint involvement in juvenile idiopathic arthritis: a pilot study comparing clinical examination and ultrasound to magnetic resonance imaging. Rheumatology (Oxford) 2009; 48(6): 680–5CrossRef
24.
Magni-Manzoni S, Epis O, Ravelli A, et al. Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis. Arthritis Rheum 2009; 61(11): 1497–504PubMedCrossRef
25.
Haslam KE, McCann LJ, Wyatt S, et al. The detection of subclinical synovitis by ultrasound in oligoarticular juvenile idiopathic arthritis: a pilot study. Rheumatology (Oxford) 2010; 49(1): 123–7CrossRef
26.
Pascoli L, Wright S, McAllister C, et al. Prospective evaluation of clinical and ultrasound findings in ankle disease in juvenile idiopathic arthritis: importance of ankle ultrasound. J Rheumatol 2010; 37(11): 2409–14PubMedCrossRef
27.
Damasio MB, Malattia C, Martini A, et al. Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatr Radiol 2010; 40(6): 985–98PubMedCrossRef
28.
Miller E, Uleryk E, Doria AS. Evidence-based outcomes of studies addressing diagnostic accuracy of MRI of juvenile idiopathic arthritis. AJR Am J Roentgenol 2009; 192(5): 1209–18PubMedCrossRef
29.
McKay GM, Cox LA, Long BW. Imaging juvenile idiopathic arthritis: assessing the modalities. Radiol Technol 2010; 81(4): 318–27PubMed
30.
Baildam E, Davidson J. BSPAR position statement on professionals working in paediatric rheumatology. Rheumatology (Oxford) 2008; 47(6): 743–4CrossRef
31.
Davies K, Cleary G, Foster H, et al. BSPAR standards of care for children and young people with juvenile idiopathic arthritis. Rheumatology (Oxford) 2010; 49(7): 1406–8CrossRef
32.
Wallace CA. Developing standards of care for patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2010; 49(7): 1213–4CrossRef
33.
Brunner HI, Ravelli A. Developing outcome measures for paediatric rheumatic diseases. Best Pract Res Clin Rheumatol 2009; 23(5): 609–24PubMedCrossRef
34.
Ringold S, Wallace CA. Measuring clinical response and remission in juvenile idiopathic arthritis. Curr Opin Rheumatol 2007; 19(5): 471–6PubMedCrossRef
35.
Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol 2004; 16(5): 566–70PubMedCrossRef
36.
Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40(7): 1202–9PubMed
37.
Albornoz MA. ACR formally adopts improvement criteria for juvenile arthritis (ACR pediatric 30). ACR News 2002; 21: 3
38.
Nugent J, Ruperto N, Grainger J, et al. The British version of the childhood health questionnaire (CHAQ) and the child health questionnaire (CHQ). Clin Exp Rheumatol 2001; 19Suppl. 23: S163–7PubMed
39.
Ruperto N, Ravelli A, Falcini F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis 1998; 57(1): 38–41PubMedCrossRef
40.
Brunner HI, Lovell DJ, Finck BK, et al. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002; 29(5): 1058–64PubMed
41.
Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31(11): 2290–4PubMed
42.
Wallace CA, Ravelli A, Huang B, et al. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006; 33(4): 789–95PubMed
43.
Wallace CA, Huang B, Bandeira M, et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005; 52(11): 3554–62PubMedCrossRef
44.
Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372(9636): 383–91PubMedCrossRef
45.
Magni-Manzoni S, Ruperto N, Pistorio A, et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008; 59(8): 1120–7PubMedCrossRef
46.
Oliveira S, Ravelli A, Pistorio A, et al. Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis. The Pediatric Rheumatology International Trials Organization Multinational Quality of Life Cohort Study. Arthritis Rheum 2007; 57(1): 35–43PubMedCrossRef
47.
Gutierrez-Suarez R, Pistorio A, Cespedes CA, et al. Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study. Rheumatology (Oxford) 2007; 46(2): 314–20CrossRef
48.
Varni JW, Seid M, Smith KT, et al. The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum 2002; 46(3): 714–25PubMedCrossRef
49.
Varni JW, Burwinkle TM, Seid M, et al. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr 2003; 3(6): 329–41PubMedCrossRef
50.
Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61(5): 658–66PubMedCrossRef
51.
Viola S, Felici E, Magni-Manzoni S, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum 2005; 52(7): 2092–102PubMedCrossRef
52.
Ravelli A. The time has come to include assessment of radiographic progression in juvenile idiopathic arthritis clinical trials. J Rheumatol 2008; 35(4): 553–7PubMed
53.
Thornton J, Beresford MW, Clayton P. Improving the evidence base for treatment of juvenile idiopathic arthritis: the challenge and opportunity facing the MCRN/ARC Paediatric Rheumatology Clinical Studies Group. Rheumatology (Oxford) 2008; 47(5): 563–6CrossRef
54.
Eberhard BA. Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. J Rheumatol 2004; 31(12): 2507–12PubMed
55.
Zulian F. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford) 2004; 43(10): 1288–91CrossRef
56.
Zulian F. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2003; 42(10): 1254–9CrossRef
57.
Lepore L. Treatment of juvenile idiopathic arthritis with intra-articular triamcinolone hexacetonide: evaluation of clinical effectiveness correlated with circulating ANA and T gamma/delta + and B CD5+ lymphocyte populations of synovial fluid. Clin Exp Rheumatol 2002; 20(5): 719–22PubMed
58.
Marti P. Factors influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis. Eur J Pediatr 2008; 167(4): 425–30PubMedCrossRef
59.
Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005; 294(13): 1671–84PubMedCrossRef
60.
Cleary AG, Murphy HD, Davidson JE. Intra-articular corticosteriod injections in juvenile idiopathic arthritis. Arch Dis Child 2003; 88: 192–6PubMedCrossRef
61.
Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48(2): 124–31PubMedCrossRef
62.
Giannini EH. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med 1992; 326(16): 1043–9PubMedCrossRef
63.
Woo P. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43(8): 1849–57PubMedCrossRef
64.
Ramanan AV. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003; 88(3): 197–200PubMedCrossRef
65.
Ruperto N. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50(7): 2191–201PubMedCrossRef
66.
Cespedes-Cruz A, Gutierrez-Suarez R, Pistorio A, et al. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 2008; 67(3): 309–14PubMedCrossRef
67.
Foell D, Frosch M, Schulze zur WA, et al. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis 2004; 63(2): 206–8PubMedCrossRef
68.
Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303(13): 1266–73PubMedCrossRef
69.
Hunter PJ, Nistala K, Jina N, et al. Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis Rheum 2010; 62(3): 896–907PubMedCrossRef
70.
Van Rossum MA. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998; 41(5): 808–16PubMedCrossRef
71.
Van Rossum MA. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007; 66(11): 1518–24PubMedCrossRef
72.
Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001; 134(8): 695–706PubMed
73.
Kelly A, Ramanan AV. Recognition and management ofmacrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol 2007; 19(5): 477–81PubMedCrossRef
74.
Foster H. Autologous haematopoeitic stem cell rescue (AHSCR) for severe rheumatic disease in children: guidance for BSPAR members. Executive summary. Rheumatology (Oxford) 2006; 45(12): 1570–1CrossRef
75.
Brinkman DM. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum 2007; 56(7): 2410–21PubMedCrossRef
76.
Abinun M, Flood TJ, Cant AJ, et al. Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000–2007). Mol Immunol 2009; 47(1): 46–51PubMedCrossRef
77.
Beresford MW, Baildam EM. New advances in the management of juvenile idiopathic arthritis: II. The era of biologicals. Arch Dis Child Educ Pract Ed 2009; 94(5): 151–6PubMedCrossRef
78.
Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007; 6(1): 75–92PubMedCrossRef
79.
Gartlehner G, Hansen RA, Jonas BL, et al. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol 2008; 27(1): 67–76PubMedCrossRef
80.
Ilowite NT. Update on biologics in juvenile idiopathic arthritis. Curr Opin Rheumatol 2008; 20(5): 613–8PubMedCrossRef
81.
Diak P, Siegel J, La GL, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010; 62(8): 2517–24PubMedCrossRef
82.
Lehman TJ. Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis? Arthritis Rheum 2010; 62(8): 2183–4PubMedCrossRef
83.
McCroskery P, Wallace CA, Lovell DJ, et al. Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 2010; 8: 18PubMedCrossRef
84.
McCann LJ, Woo P. Biologic therapies in juvenile idiopathic arthritis: why and for whom? Acta Reumatol Port 2007; 32(1): 15–26PubMed
85.
Finckh A. At the horizon of innovative therapy in rheumatology: new biologic agents. Curr Opin Rheumatol 2008; 20(3): 269–75PubMedCrossRef
86.
Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342(11): 763–9PubMedCrossRef
87.
Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359(8): 810–20PubMedCrossRef
88.
Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56(9): 3096–106PubMedCrossRef
89.
Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371(9617): 998–1006PubMedCrossRef
90.
Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58(5): 1496–504PubMedCrossRef
91.
Prince FH. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 2009; 68(5): 635–41PubMedCrossRef
92.
Horneff G. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009; 68(4): 519–25PubMedCrossRef
93.
Vojvodich PF. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol 2007; 34(12): 2481–5PubMed
94.
Gerloni V. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 2005; 52(2): 548–53PubMedCrossRef
95.
Lahdenne P. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003; 62(3): 245–7PubMedCrossRef
96.
Quartier P. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48(4): 1093–101PubMedCrossRef
97.
Horneff G. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63(12): 1638–44PubMedCrossRef
98.
99.
Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatolol 2006; 2(1): 28–34CrossRef
100.
WooP. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7(6): R1281–8CrossRef
101.
Hoffmann-La Roche. A study of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis [ClinicalTrials.gov identifier NCT00988221]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov/​ct2/​show/​NCT00988221 [Accessed 2011 Jan 28]
102.
Lequerre T. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67(3): 302–8PubMedCrossRef
103.
Woo P. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. Ann Rheum Dis 2008; 67(3): 281–2PubMedCrossRef
104.
Ohlsson V. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 2008; 47(4): 555–6CrossRef
105.
Gattorno M. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58(5): 1505–15PubMedCrossRef
106.
Novartis Pharmaceuticals. Single-dose study to assess efficacy of canakinumab (ACZ885) in patients with active systemic juvenile idiopathic arthritis [SJIA] (β-SPECIFIC 1) [ClinicalTrials.gov identifier NCT00886769]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov/​ct2/​show/​NCT00886769 [Accessed 2011 Jan 28]
107.
Novartis Pharmaceuticals. Flare prevention study of canakinumab in patients with active systemic juvenile idiopathic arthritis [SJIA] (β-SPECIFIC 2) [ClinicalTrials.gov identifier NCT00889863]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov/​ct2/​show/​NCT00889863 [Accessed 2011 Jan 28]
108.
Novartis Pharmaceuticals. An open-label extension study of canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic manifestations (β-SPECIFIC 3) [ClinicalTrials.gov identifier NCT00891046]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov/​ct2/​show/​NCT00891046 [Accessed 2011 Jan 28]
109.
Feldman BM. Treating children with arthritis: towards an evidence-based culture. J Rheumatol Suppl 2005; 72: 33–5PubMed
110.
Metadaten
Titel
Juvenile Idiopathic Arthritis
New Insights into Classification, Measures of Outcome, and Pharmacotherapy
verfasst von
Dr Michael W. Beresford
Publikationsdatum
01.06.2011
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 3/2011
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/11588140-000000000-00000

Weitere Artikel der Ausgabe 3/2011

Pediatric Drugs 3/2011 Zur Ausgabe

Erratum

Erratum to Spotlight on Tdap5 Vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged ≥4 years), adolescents, and adults

Review Article

Antiretroviral Drugs in Pediatric HIV-Infected Patients

Original Research Article

Folate Fortification and Survival of Children with Acute Lymphoblastic Leukemia

Adis Drug Profile

Aripiprazole

Review Article

Targeting Airway Inflammation in Cystic Fibrosis in Children

Review Article

Intestinal Transplantation in Children

Neu im Fachgebiet Pädiatrie

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

Embryotransfer erhöht womöglich Leukämierisiko der Kinder

13.05.2024 Assistierte Reproduktion Nachrichten

Reproduktionsmedizinische Techniken haben theoretisch das Potenzial, den epigenetischen Code zu verändern und somit das Krebsrisiko der Kinder zu erhöhen. Zwischen Embryotransfer und Leukämie scheint sich ein solcher Zusammenhang bestätigt zu haben.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise